Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study

NCT00683514 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT00683514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00683514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
Not reported
Enrollment
201 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc